ArticleAbdominal radiology (New York)2026
Imaging features of TSC2/PKD1 contiguous gene deletion syndrome in adults.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo report the first detailed description of the radiological features of tuberous sclerosis complex 2/polycystic kidney disease 1 (TSC2/PKD1) contiguous gene deletion syndrome (CGS), a rare and poorly reported or described syndrome.
methodsThis multicenter retrospective study included 9 adult patients (6 women, 3 men; mean age, 29±8 years) with genetically confirmed TSC2/PKD1 CGS. Clinical data and imaging studies (MRI, CT, ultrasound) were reviewed independently by two radiologists. Radiological features assessed included kidney length, total kidney volume (TKV), height-adjusted TKV (hTKV), cyst burden, angiomyolipomas (AMLs), and extrarenal manifestations.
resultsAll patients presented with enlarged polycystic kidneys (mean TKV: 2134 ± 904 mL; mean hTKV: 1260 ± 471 mL/m) and a high cyst burden (median 45 cysts per kidney); 7 of 8 classifiable patients (88%) were assigned to Mayo imaging class 1E, a classification validated in ADPKD whose prognostic value cannot be directly transposed to CGS, where renal volume also reflects solid angiomyolipomatous tissue. AMLs were observed in 78% of cases, with both fat-rich and fat-poor subtypes. One patient developed a hemorrhagic AML requiring embolization and underwent nephrectomy for a growing fat-poor lesion, ultimately diagnosed as AML. End-stage renal disease occurred in 67% of patients at a median age of 25 years. Extrarenal findings included cerebral cortical tubers and subependymal nodules in all patients, hepatic cysts (56%), hepatic AMLs (33%), pulmonary lymphangioleiomyomatosis (22%), and cardiac rhabdomyomas (22%).
conclusionAdult patients with TSC2/PKD1 CGS exhibit a distinct imaging phenotype characterized by features of both ADPKD and TSC. The identification of AML in the context of ADPKD-like cystic disease should prompt consideration of CGS. Early diagnosis is crucial for guiding appropriate follow-up, therapeutic interventions, and genetic counseling.
Indexed as
Identifiers
42696112What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.